July 16th, 2014
HPS2-THRIVE: The Final Chapter in the Niacin Story?
Nicholas Downing, MD and Harlan M. Krumholz, MD, SM
Findings from HPS2-THRIVE raise uncomfortable questions for physicians.
NEJM Journal Watch — Recent Cardiology Articles- More Data on Finerenone for Heart Failure with Preserved or Mildly Reduced Ejection Fraction
- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?